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ABSTRACT
Background: Mild cognitive impairment (MCI) of an
amnestic type is a common condition in older people
and highly predictive of Alzheimer’s disease (AD). To
date, there is no clear consensus regarding the best
antecedent biomarker to predict early conversion to AD.
Objective: The aim of the study is to demonstrate that
1H magnetic resonance spectroscopy (MRS) of the
brain in MCI patients may predict early conversion to
dementia within the 2-year period after baseline
assessment.
Methods: A cohort of patients fulﬁlling the criteria of
amnestic MCI were enrolled consecutively. At baseline
the patients underwent neuropsychological
examination, standard blood tests and APOE genotype.
1H-MRS (1.5 T) of the brain was carried out by
exploring two areas: the posteromedial bilateral
parietal lobe and left medial occipital lobe. The patients
were followed up to detect conversion to probable AD
according to the National Institute of Neurological and
Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
group criteria.
Results: After a 2-year follow-up, 27 (38%) patients
converted to AD. The mean N-acetyl-aspartate/creatine
(NAA/Cr) ratio in the posteromedial bilateral parietal
cortex was 1.38 in converters versus 1.49 in non-
converters (p<0.0001). An NAA/Cr ratio equal to or
lower than 1.43 in this area predicted conversion to
probable AD at 74.1% sensitivity and 83.7% speciﬁcity
(area under the curve: 0.84; 95% CI 0.73 to 0.92). The
cross-validated accuracy of classiﬁcation was 82%,
which reaches 85% when the APOE4 genotype and
memory test are included in the analysis. In the left
medial occipital lobe, the predictive value was
somewhat lower with 85.2% sensitivity and 61.4%
speciﬁcity (area under the curve: 0.8; 95% CI 0.69 to
0.89). Neither the APOE4 genotype nor leuco-araiosis
was predictive of conversion to dementia.
Conclusion: MRS is a valuable biomarker to
predict early conversion to dementia in patients with
amnestic MCI.
Amnestic MCI is a common condition in
older people mainly characterised by
memory loss. Although there may be other
subtle inefﬁciencies, the general cognitive
function and daily living activities are
preserved.
1 The meaning of this concept
varies across the scientiﬁc community:
a transitional state between normality and
dementia,
1 an early phase of AD
2 or an
unstable condition that may evolve to
dementia or may even revert to normality.
3
Regardless of conceptualisation, most
patients convert to AD over time, but some of
them remain non-demented. A meta-analysis
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ARTICLE SUMMARY
Article focus
- Amnestic mild cognitive impairment (MCI) is
a common condition at increased risk of
conversion to Alzheimer’s disease (AD). There
is no clear consensus regarding the ideal
antecedent biomarker to predict early conver-
sion.
- There are a few longitudinal studies using brain
magnetic resonance spectroscopy (MRS) as
a predictor of conversion to dementia.
- We hypothesise that MRS in MCI may identify
patients at risk of early conversion to dementia.
Key messages
- MRS is a reliable biomarker of AD and predicts
early conversion to dementia in MCI.
- Both posteromedial parietal and occipital regions
were predictive of conversion, but the parietal
region was better in terms of accuracy of
classiﬁcation.
- Neither the APOE4 genotype nor leuco-araiosis
was predictive of conversion.
Strengths and limitations
- This is a longitudinal study, which is a non-
invasive, reproducible and widely available tool.
However, this technique is not free of artefacts
limiting the accuracy of metabolite levels.
- This study is based on early predictions (2 years
from baseline). In the longer term, it is likely that
all patients with objective memory impairment
will convert to dementia.
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Open Access Researchfrom clinical trials in MCI has revealed that treatment
with cholinesterase inhibitors does not delay the onset of
AD.
45However, in patients with mild to moderate AD,
cholinesterase inhibitors can delay cognitive decline and
deterioration in global health for at least 6 months.
6
Given that it is not cost-effective to treat all MCI patients,
we need a biomarker to predict conversion to dementia
to start treatment as soon as possible in those at high
risk.
Since brain pathology starts long before symptoms in
AD, many studies have focused on antecedent
biomarkers of AD to diagnose this disease in the early
phase called MCI or even before. It is true that the
atrophy of the medial temporal lobe structures, such as
entorhinal cortex and hippocampus, has yielded
encouraging results,
7e16 and cerebrospinal ﬂuid (CSF)
biomarkers (s and Ab42 proteins) as well
17e24 with large
intra- and interindividual variations. So far, no stand-
ardised procedures have been established.
Studies with PET in MCI and AD show the areas
involved in early phases. The posterior cingulate gyrus
(PCG) is an area involved in memory and many times
studied in MCI and AD. The patients with AD had
a lower glucose metabolism than healthy controls in
parietal, temporal, occipital, frontal and posterior
cingulate cortices.
25 FDDNP-PET (radiotracer binding to
plaques and tangles)
26 and FDG-PET
27 ﬁndings can
discriminate normality from MCI and AD, with the PCG
being one of the most typically affected areas. In longi-
tudinal studies, PET has yielded the highest accuracies to
predict conversion to dementia, but most studies
included small cohorts of MCI patients.
28e31
Several cross-sectional studies with MRS found
decreased N-acetyl-aspartate/creatine (NAA/Cr) ratios
and increased myo-inositol/creatine (mI/Cr) ratios in
the PCG of MCI and AD patients in comparison with
controls,
32e35 and in the occipital lobe of AD patients in
comparison with controls
36 37 and vascular dementia.
38
Longitudinal studies with MRS are scarce. In a cohort
with 53 MCI patients, the occipital NAA/Cr ratios, but
not those of the hippocampus and mid-parietal lobe,
were predictive of conversion to dementia with high
accuracy.
39 In another cohort of 119 MCI patients, the
NAA/Cr ratios in the left occipital lobe were compared
with those obtained in the posteromedial parietal cortex
(PMPC), yielding similar predictive values, with the
PMPC values being slightly more signiﬁcant than those
observed in the occipital lobe. This study included
amnestic and multiple-domain MCI. At baseline,
a signiﬁcant correlation was observed between the ratios
observed in these two locations.
40 Another small cohort
(25 MCI patients) study showed that the NAA/Cr ratios
in the left paratrigonal area were also predictive of
conversion to dementia.
41 In a large cohort of 151 MCI
patients (most being of the amnestic type) followed up
for 3 years, MRS was individually predictive of conversion
to dementia, but the accuracy of prediction improved
when MRS was used in combination with hippocampal
volumetry and the presence of cortical infarctions.
42 In
a small cohort of MCI (15) patients and controls (12),
the ratios of NAA/Cr in the parietal lobe decreased
longitudinally more in patients who converted to
dementia than in non-converters.
43
On the basis of all of the above and, given the paucity
of longitudinal MRS studies in MCI, the purpose of this
work is to investigate whether MRS measuring cerebral
baseline NAA/Cr ratios in amnestic MCI are predictive
of early conversion to dementia. We hypothesise that the
occipital and parietal values are similarly predictive of
conversion to dementia.
PATIENTS AND METHODS
A cohort of patients fulﬁlling the criteria of amnestic
MCI according to the Petersen et al
1 were recruited
consecutively. The patients were referred by family
physicians because of memory complaints corroborated
by an informant. Those included in our cohort were ﬁrst
screened for memory impairment with the Memory
Impairment Screen (MIS).
44 In the MIS, four written
words are presented to the patient, who must read aloud
and memorise the words. After a period of 5 min, the
patient is asked to recall these words; 2 points are given
for every word recalled spontaneously, and 1 point is
given for every word recalled with cues. At baseline, the
patients underwent neuropsychological analysis encom-
passing the Mini-Mental test (Spanish version with
a maximum possible score of 35 points),
45 the Blessed
Dementia Rating Scale, the clock drawing test, the
Geriatric Depression Scale and the Rey Auditory Verbal
Learning Test (RAVLT) delayed recall. The patients
included in this study must score 5 or lower in the MIS,
0.5 in the CDR and a score in the Mini-Mental higher
than 21 points. The cut-off points for the RAVLT 20 min
delayed recall were as follows: #4 for patients aged up to
69 and #3 for patients aged 70 and older. Those who
scored 11 points or higher in the Geriatric Depression
Scale were re-evaluated after antidepressant treatment,
so as to conﬁrm that they had MCI.
The patients fulﬁlling the criteria mentioned above
also underwent standard blood tests, including
vitamin B12, serological test of syphilis and thyroid
hormones. APOE genotype was also determined. Brain
magnetic resonance techniques were also carried out as
follows. All patients underwent brain T1- and T2-
weighted MRI on a 1.5 Tclinical scanner (Signa HD, GE,
Milwaukee, Wisconsin). Single-voxel
1H-MRS was carried
out by means of an echo time (TE) of 35 ms and
a repetition time (TR) of 2000 ms with a spin echo
technique that uses selective excitation with gradient
spoiling for water suppression. The mode of spectral
acquisition was probe-p (PRESS technique). The pure
metabolite signal was spoiled, zero-ﬁlled and Fourier-
transformed to produce a spectrum, scaled, drawn onto
a 5123512 image, and stored as an image in the system
database. Every spectrum was automatically ﬁtted to four
peaks corresponding to levels of N-acetyl-aspartate
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MRS as biomarker of early Alzheimer’s disease(NAA), 2.02 ppm; total creatine (Cr), 3.03 ppm; choline-
containing compounds (Ch), 3.23 ppm; and myo-
Inositol (mI), 3.56 ppm. We also obtained the peak
amplitude of the metabolites relative to creatine. For this
purpose, we used the algorithms provided by the GE
software (Signa HD, GE software release 12.x), version
3.0, with the following steps: (1) setting a global
frequency ﬁt parameter; (2) performing line-width and
line-shape enhancement by appropriate apodisation of
the time-domain signal; (3) Fourier transformation of
the signal to the appropriate frequency resolution and
number of points; (4) calculation of a baseline correc-
tion from the frequency-domain signal; (5) and curve-
ﬁtting the desired regions of the frequency-domain
signal. The volume voxel was 23232 cm in each area
explored. These areas of exploration were the left
medial occipital lobe and the posteromedial parietal
area bilaterally encompassing the posterior cingulated
gyrus and the inferior precuneus (see ﬁgure 1). Spectra
were rejected and repeated in the following cases: line
width >10 Hz, line shape asymmetrical after eddy-
current correction and the presence of artefacts. Data
ﬁts with %SD>20 from the Crame ´reRao inequality were
eliminated.
Both areas we examined showed excellent reproduc-
ibility in two previous studies of testeretest reliability
carried out with the same clinical scanner in AD
patients.
46 47 For the NAA/Cr ratios, the a value was 0.93
and 0.95 in the posteromedial bilateral parietal lobe
respectively, and 0.89 and 0.87 in the left medial occip-
ital lobe. In spite of these good a values seen previously,
we also carried out a second immediate MRS in 22
patients without their being removed from the scanner
to check reproducibility. The intraclass correlation
coefﬁcients were 0.92 and 0.9 for parietal and occipital
lobes respectively.
At baseline, we also carried out MRS in 35 healthy
elderly controls with the voxels located in the same areas
for comparison purposes. The subjects were healthy
volunteers who agreed to participate to establish
a normative group. The mean age was 70.3 (SD
7.8) years, and there were 23 women and 12 men.
The recruitment started in October 2007 and ﬁnished
in July 2008. The patients were followed up and re-eval-
uated every 6 months or earlier to determine if they had
converted to probable AD-type dementia according to
the National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association group criteria.
48
Reassessment was based on the Mini-Mental, MIS,
Blessed Dementia Rating Scale and clock drawing tests.
Statistical analysis
Quantitative variables such as metabolite values in
converters and non-converters were compared using two-
tailed t tests. Survival analysis was based on the
KaplaneMeier method and Cox proportional hazards
model. According to the metabolite values found in
MRS, we divided the patients into two groups: those with
NAA/Cr ratios below the mean and those with mean
values and higher. The proportions of patients free of
conversion to dementia in each group were compared
with the logrank test. The proportion of patients who
did not convert to dementia was adjusted for potential
confounders such as age, educational level, global
cognitive function at baseline, memory and APOE
genotype with the Cox regression model.
The predictive values of the different variables
(APOE4, memory tests and brain metabolite values)
were calculated with the analysis of receiver operating
characteristic (ROC) curves. Parameters such as sensi-
tivity, speciﬁcity, positive and negative predictive values,
and accuracy of classiﬁcations are reported. The results
were cross-validated using a discriminant analysis and
leave-one-out technique. ROC curves were analysed
using Med-Calc software, and the other statistical tech-
niques using SPSS software, version 10.
We obtained informed consent from patients and
relatives. This study was approved by our regional ethical
committee.
Figure 1 (A) Axial T2-weighted
MRI. Voxel placement in the left
occipital lobe. (B) Sagittal
T1-weighted MRI. Voxel
placement in the posteromedial
parietal cortex bilaterally.
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MRS as biomarker of early Alzheimer’s diseaseRESULTS
Initially, we recruited a cohort of 78 patients who scored
5 or lower in the MIS and fulﬁlled the criteria of
amnestic MCI. However, MRS was not possible in six
cases; three had claustrophobia, two wore a pacemaker,
and one refused to participate. One patient had to be
excluded because of an incidental brain-stem tumour.
Therefore, 71 patients were ﬁnally included in the study.
Table 1 lists the main baseline demographic variables
and the results of memory tests and scales. There were
no differences with regard to the female/male ratio
between patients and controls, but the controls were
somewhat younger than the patients (mean: 70.3 vs
74 years; p¼0.01). The mean age of the seven excluded
patients was 76.4 years.
At baseline MRI (T1, T2 and ﬂuid-attenuated inver-
sion recovery sequences) we detected the following
abnormalities: diffuse cortical atrophy in 40 patients,
isolated hippocampal atrophy in nine patients, leuco-
araiosis in 38 patients and microinfarctions in six
patients. Atrophy was evaluated only visually.
After a mean follow-up of 22 (range: 6e34) months, 27
(38%) patients out of 71 converted to probable AD
according to the National Institute of Neurological and
Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
criteria, and none of them reverted to normality. None
of the converters showed any symptoms or signs of
parkinsonism, hallucinations, cognitive ﬂuctuations or
focal symptoms. No differences were seen in the male/
female ratio proportion, but converters were older than
non-converters (mean age: 76 (SD 6.5) years for converters
vs 73 (SD 5.8) years for non-converters; p¼0.01).
Spectroscopic results
Controls versus MCI patients
Table 2 lists the values of the different variables for
converters and non-converters, and also for controls.
When we compared the NAA/Cr ratios in the occipital
lobe of the 71 MCI patients with 35 controls, we found
signiﬁcant differences: 1.56 (SD 0.09) in patients in
comparison with 1.65 (SD 0.08) in controls (t¼5;
p<0.0001). No signiﬁcant differences were seen in the
rest of metabolite ratios. In the PMPC, no global differ-
ences were observed in the mean NAA/Cr ratios: 1.46
for controls and 1.45 for MCI patients. The differences
in the NAA levels were signiﬁcant: 134.06 (SD 18.3) for
controls versus 123.17 (SD 17.3) for MCI patients
(t¼2.99; p¼0.003). We did not ﬁnd any signiﬁcant
differences for the other metabolites and ratios.
Converters versus non-converters
The mean NAA/Cr ratio in the posteromedial cortex was
1.30 (SD 0.09) in converters versus 1.49 (SD 0.08) in
non-converters (t¼9.96; p<0.0001). In the occipital lobe
Table 1 Demographic variables and scales scores in the
cohort of 71 patients with amnestic mild cognitive
impairment
Variables (N[71)
Age, years 74.6 (SD 6.4; range 58e88)
Sex 43 female
MEC 28.4 (SD 3.1; range 21e34)
Blessed Dementia
Rating Scale
2.8 (SD 0.9; range 1e4)
Memory Impairment
Screen
2.4 (SD 1.7; range 0e5)
Rey Auditory Verbal
Learning Test
3.1 (SD 2.5; range 0e6)
in delayed recall
Educational level
Elementary education,
n patients
65
High school education,
n patients
6
Higher education,
n patients
4
Hypertension, n (%) 24 (33.8)
APOE4 genotype 21 had one or two alleles
Mean follow-up, months 22 (range 6e34)
Mean no of visits 4.4 (range 3e7)
Table 2 Metabolite levels and ratios to creatine in the two areas explored with Magnetic Resonance Spectroscopy
Variable Controls (n[35) Converters (n[27) Non-converters (n[44) p Value
Posteromedial parietal cortex
NAA 134 (18.3) 120 (19.89) 125.8 (15.59) NS
NAA/Cr 1.46 (0.08) 1.38 (0.09) 1.49 (0.08) <0.0001
Ch/Cr 0.61 (0.07) 0.62 (0.05) 0.59 (0.1) NS
mI/Cr 0.66 (0.08) 0.63 (0.08) 0.6 (0.09) NS
NAA/mI 2.19 (0.35) 2.4 (0.29) 2.3 (0.29) NS
Occipital lobe
NAA 133.3 (23.1) 133.7 (25.1) 146.9 (24.4) 0.03
NAA/Cr 1.65 (0.08) 1.49 (0.08) 1.6 (0.08) <0.0001
Ch/Cr 0.6 (0.07) 0.55 (0.05) 0.57 (0.07) NS
mI/Cr 0.65 (0.1) 0.59 (0.06) 0.6 (0.07) NS
NAA/mI 2.52 (0.36) 2.63 (0.29) 2.61 (0.4) NS
Statistical signiﬁcance refers to the differences found between converters and non-converters. Statistical signiﬁcance is represented by the
p value on the right column
Ch, choline; Cr, creatine; mI, myo-inositol; NAA, N-acetyl-aspartate; NS, not signiﬁcant.
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MRS as biomarker of early Alzheimer’s diseaseit was 1.48 (SD 0.08) in converters versus 1.6 in non-
converters (t¼4.89; p¼0.0001). The absolute occipital
NAA level was 133.7 (SD 25.1) in converters versus 146.9
(SD 24.4) in non converters (p¼0.03). Figure 2A,B
presents an example in a non-converter and converter
respectively. The differences were not signiﬁcant for the
other metabolite values (see table 2). It is worth
mentioning that the baseline NAA/Cr values in the
posteromedial and occipital cortices correlated signiﬁ-
cantly (r¼0.56; p<0.0001) in the whole sample of 71
patients.
In the survival analysis, we saw signiﬁcant differences
in the proportion of dementia-free patients at follow-up
(see ﬁgures 3, 4). The patients with NAA/Cr ratios below
the mean were more likely to convert to dementia than
those with values above the mean in both posteromedial
parietal (logrank test: 17.83, p<0.0001) and occipital
lobe (logrank test: 11.7; p¼0.0007). The differences
were adjusted for potential confounders (age, educa-
tional level, global cognitive function, memory scale
and APOE genotype) with the Cox regression model.
Only global cognition Mini Examen Cognoscitivo
(MEC) and memory scale (RAVLT) at baseline were also
predictive of conversion to dementia. The adjusted HR
for the NAA/Cr ratios below the mean in the poster-
omedial parietal lobe was 7.03 (95% CI 2.6 to 18.9). In
the occipital lobe, the HR was 5.06 (96% CI 1.73 to
14.8). The results were also predictive when NAA/Cr
ratios were factored out as continuous variables.
An NAA/Cr ratio equal to or lower than 1.43 in the
posteromedial bilateral parietal cortex predicted
conversion to probable AD at 74.1% sensitivity and
83.7% speciﬁcity, with a positive predictive value of
74.1% and a negative predictive value of 83.7%. The area
under the curve was 0.84 (95% CI 0.73 to 0.92). The
cross-validated accuracy of classiﬁcation was 82%,
reaching 85% when the APOE genotype and memory
test were included in the analysis. In the left medial
occipital lobe, the predictive value was somewhat lower
with 85.2% sensitivity, 61.4% speciﬁcity, a positive
predictive value of 57.5% and a negative predictive value
of 87.1%. The area under the curve was 0.8 (95% CI 0.69
to 0.89). The ROC curves are presented in the ﬁgure 5.
Figure 2 (A) Example of a spectrum in the parietal lobe in
a non-converter. (B) Example of a spectrum in a converter.
The N-acetyl-aspartate (NAA) peak is lower than in the
previous example in relation to creatine. Ch, choline
compounds; Cr, creatine; mI, myo-inositol.
Figure 3 Comparison of survival curves for the variable
N-acetyl-aspartate/Cr in the posteromedial parietal cortex. The
curves represent the proportion of patients not converting to
dementia across the time according to the NAA/Cr ratios.
Upper curve: patients with ratios equal to or above mean.
Lower curve: patients with ratios below mean.
Figure 4 Comparison of survival curves for the variable
N-acetyl-aspartate/Cr in the left occipital lobe. Proportion of
patients free of dementia across the time in the patients with
an N-acetyl-aspartate/Cr ratio equal to or higher than the
mean (upper curve) and in those with ratios below the mean
(lower curve).
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MRS as biomarker of early Alzheimer’s diseaseThe APOE4 genotype alone yielded low predictive
values in terms of sensitivity as 18 patients converted to
dementia despite not having APOE4 alleles, and only
eight of converters had one or two alleles (33% sensi-
tivity and 72% speciﬁcity). The RAVLT yielded a low
sensitivity but high speciﬁcity (55.6% and 84% respec-
tively). The presence/absence of white-matter hyper-
intensities (leuco-araiosis) was not predictive of
conversion to dementia.
DISCUSSION
The diagnosis of AD in early phases is still challenging.
Several tools, clinical and radiological, have been used so
far, but there is no consensus on which is best. In addi-
tion, the techniques determined are not available in
every medical centre, so each department should take
advantage of those available.
MRS represents a valuable technique in AD on the
basis of previous cross-sectional and longitudinal
published works. Additionally it was found that MRS
correlates well with histopathology. The NAA levels were
lower in the brain of AD than in controls and that this
decrease was correlated with the number of neuritic
plaques and neuroﬁbrillar tangles in tissue sections.
49
The value of proton MRS as a biomarker has also been
assessed ante mortem in a series of 54 patients ranging
from a low to high likelihood of having AD and those
who underwent an autopsy. Decreases in NAA/Cr and
increases in mI/Cr ratios were correlated with higher
Braak neuropathological stages in the posterior bilateral
cingulate gyrus.
50 Furthermore, the value of MRS as
a biomarker has been conﬁrmed by the fact that changes
in metabolite ratios are detected years before the clinical
onset of AD in subjects carrying mutations in preseni-
lins
51 or protein s
52 genes.
The predictive NAA/Cr ratios of the posteromedial
parietal lobe agree with the early involvement of the
PCG in AD but its occurrence in the occipital lobe may
be surprising, as histopathological changes appear in
more advanced stages of the disease. However, two
cross-sectional studies with MRS showed lower NAA/Cr
ratios in AD patients than in controls in the occipital
cortex,
36 37 and one study in MCI showed lower NAA/
Cr ratios in converters than in converters.
39 Two more
studies point to an earlier involvement than previously
thought for the occipital cortex in AD. A PET study in
13 patients with mild to moderate AD revealed that
glucose metabolism was correlated to cognitive perfor-
mance in the parietal lobes, but for the activation
condition, the authors also found correlations within
the primary and association visual areas.
53 A neuro-
pathological study revealed dense AD pathology in area
19 in some subjects with preclinical AD and in all
patients with MCI, and noted that it was present even
in the absence of hippocampal and entorhinal
pathology.
54
Apart from the intrinsic predictive value of
a biomarker, this should be weighed in comparison with
other biomarkers available. On the one hand, volumetry
of the medial temporal lobe structures is widely used but
not without its limitations (artefacts, lack of stand-
ardisation, complexity and long duration for the
process). On the other hand, the CSF biomarkers need
an invasive procedure and admission to hospital.
Furthermore, these biomarkers do not differ greatly
from MRS in terms of accuracy of prediction. At a ﬁxed
80% speciﬁcity, the hippocampus plus entorhinal cortex
volume predicted conversion to AD at 66.7% sensitivity
in a cohort of 139 MCI patients followed up for 5 years.
16
According to a large prospective multicentre cohort
results with 750 MCI subjects followed up for a minimum
of 2 years, the combination of Ab42/P-s ratio and T-s in
the CSF predicted conversion to AD with a sensitivity of
83%, a speciﬁcity of 72%, a positive predictive value of
62% and a negative predictive value of 88%, but the
analytical techniques are pending standardisation.
24 PET
appears to be a robust predictor of conversion to
dementia, but it is expensive and of limited availability.
The excellent values found in the previous studies with
PET
28e31 have not been conﬁrmed in the cohort of the
AD Neuroimaging Initiative group where the positive
predictive value was 41%, and the negative predictive
value was 79%.
55
PET with Pittsburg radiotracer (amyloid plaques
binding) also seems promising in terms of speciﬁcity. In
a study including 31 MCI patients, only 17 were PIB
positive at baseline, and 14 (82%) of them converted to
dementia over a 3 year follow-up. However, only 17 MCI
patients (55%) were PIB-positive at baseline.
56
In this context of expensive and sophisticated tech-
niques, it should be borne in mind that
Figure 5 Comparison of the receiver operating characteristic
curves for the N-acetyl-aspartate/Cr ratio in the posteromedial
parietal cortex (continuous line) and the N-acetyl-aspartate/Cr
ratio in the left occipital lobe (discontinuous line). Each curve
represents the estimations of prediction of conversion to
dementia for each of either variables. All predictive values are
given in the text.
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MRS as biomarker of early Alzheimer’s diseaseneuropsychological tests can reveal good predictions of
conversion to dementia in experienced hands.
57
Of course, MRS also has some shortcomings. First, with
the large voxels analysed, it is sensitive to artefacts in the
magnetic ﬁeld and partial volume effect in areas near
osseous structures and cerebral ventricles.
58 For this
reason, it is likely that in our previous cohort, we did not
ﬁnd any predictive values in the hippocampus, although
this area is theoretically involved very early in AD. It is
expected that modern 3T scanners with smaller voxel
analysed will overcome these limitations.
59 60 Second,
quantiﬁcation of absolute metabolite values is complex,
so the metabolite ratios to creatine are much more
reliable than the absolute levels, as they can minimise
systematic errors.
61 For example, in table 2 the controls
had lower NAA levels in the occipital lobe than did non-
converters, whereas the NAA/Cr ratios were higher in
controls as it is expected to occur. Third, we were not
able to make any corrections for atrophy and CSF.
In conclusion, MRS is a useful technique as
a biomarker in early AD, as it predicts early conversion to
dementia. Although inferior to FDG-PET, it could yield
a similar performance to structural neuroimaging and
CSF biomarkers. We think MRS may play a role where no
better instruments are available.
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